Company: PRME
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001628280-25-018704
Chunk: 29

Company: Prime Medicine, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 29
---
 57,188 |     |               |   237,528 |     |              |      — |     |       |   294,716 |
| Kaye Foster (3)                |     |                 | 57,000 |     |               |   237,528 |     |              |      — |     |       |   294,528 |
| Michael Kelly (3)              |     |                 | 61,250 |     |               |   237,528 |     |              |      — |     |       |   298,778 |
| Jeffrey Marrazzo (4)           |     |                 | 44,125 |     |               | 1,731,828 |     |              | 41,667 |     |       | 1,817,620 |
| Robert Nelsen (3)              |     |                 | 50,063 |     |               |   237,528 |     |              |      — |     |       |   287,591 |
| David Schenkein, M.D. (3)      |     |                 | 60,063 |     |               |   237,528 |     |              |      — |     |       |   297,591 |

(1) Amounts represent annual cash compensation earned for services rendered as directors by non-employee members of our Board and the committees thereof during the fiscal year ended December 31, 2024.

(2) Amounts reflect the aggregate grant date fair value of option awards granted during 2024 in accordance with our Non-employee Director Compensation Policy, described below, calculated in accordance with the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, Compensation—Stock Compensation . Such grant date fair values do not take into account any estimated forfeitures. See Note 2 to our audited consolidated financial statements appearing in our 2024 Annual Report for assumptions underlying the valuation of equity awards. The amounts reported in this column reflect the accounting cost for these options and do not correspond to the actual economic value that may be received by our directors upon the exercise of the options or any sale of the underlying shares of common stock.

(3) As part of the annual Board member grants, Dr. Cahill, Dr. Chung, Ms. Foster, Mr. Kelly, Mr. Nelsen, and Dr. Schenkein received options to purchase 45,000 shares